View Item 

Show simple item record

Multinational Qualitative Research Study Exploring the Patient Experience of Raynaud’s Phenomenon in Systemic Sclerosis

dc.contributor.authorPauling, John D.
dc.contributor.authorDomsic, Robyn T.
dc.contributor.authorSaketkoo, Lesley A.
dc.contributor.authorAlmeida, Celia
dc.contributor.authorWithey, Jane
dc.contributor.authorJay, Hilary
dc.contributor.authorFrech, Tracy M.
dc.contributor.authorIngegnoli, Francesca
dc.contributor.authorDures, Emma
dc.contributor.authorRobson, Joanna
dc.contributor.authorM, Neil J.
dc.contributor.authorHerrick, Ariane L.
dc.contributor.authorMatucci‐cerinic, Marco
dc.contributor.authorKhanna, Dinesh
dc.contributor.authorHewlett, Sarah
dc.date.accessioned2018-09-04T20:08:29Z
dc.date.available2019-11-01T15:10:32Zen
dc.date.issued2018-09
dc.identifier.citationPauling, John D.; Domsic, Robyn T.; Saketkoo, Lesley A.; Almeida, Celia; Withey, Jane; Jay, Hilary; Frech, Tracy M.; Ingegnoli, Francesca; Dures, Emma; Robson, Joanna; M, Neil J.; Herrick, Ariane L.; Matucci‐cerinic, Marco ; Khanna, Dinesh; Hewlett, Sarah (2018). "Multinational Qualitative Research Study Exploring the Patient Experience of Raynaud’s Phenomenon in Systemic Sclerosis." Arthritis Care & Research 70(9): 1373-1384.
dc.identifier.issn2151-464X
dc.identifier.issn2151-4658
dc.identifier.urihttps://hdl.handle.net/2027.42/145531
dc.publisherSage
dc.publisherWiley Periodicals, Inc.
dc.titleMultinational Qualitative Research Study Exploring the Patient Experience of Raynaud’s Phenomenon in Systemic Sclerosis
dc.typeArticleen_US
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelGeriatrics
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/145531/1/acr23475.pdf
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/145531/2/acr23475_am.pdf
dc.identifier.doi10.1002/acr.23475
dc.identifier.sourceArthritis Care & Research
dc.identifier.citedreferenceDziadzio M, Denton CP, Smith R, Howell K, Blann A, Bowers E, et al. Losartan therapy for Raynaud’s phenomenon and scleroderma: clinical and biochemical findings in a fifteenâ week, randomized, parallelâ group, controlled trial. Arthritis Rheum 1999; 42: 2646 â 55.
dc.identifier.citedreferenceKirwan JR, Bartlett SJ, Beaton DE, Boers M, Bosworth A, Brooks PM, et al. Updating the OMERACT filter: implications for patientâ reported outcomes. J Rheumatol 2014; 41: 1011 â 5.
dc.identifier.citedreferenceUS Department of Health and Human Services. Guidance for industry: patientâ reported outcome measures: use in medical product development to support labeling claims. 2009. URL: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM193282.pdf.
dc.identifier.citedreferenceKrueger R, Casey M. Focus groups: a practical guide for applied research. 3rd ed. Thousand Oaks (CA): Sage; 2000.
dc.identifier.citedreferenceVan den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2013; 65: 2737 â 47.
dc.identifier.citedreferencePatton MQ. Qualitative research and evaluation methods. 3rd ed. Thousand Oaks (CA): Sage; 2002.
dc.identifier.citedreferenceGuest G, Bunce A, Johnson L. How many interviews are enough? An experiment with data saturation and variability. Field Methods 2006; 18: 59 â 82.
dc.identifier.citedreferenceYamaoka K, Miyasaka N, Sato K, Nishioka K, Okuda M. Therapeutic effects of CSâ 570, a chemically stable prostacyclin derivative, on Raynaud’s phenomenon and skin ulcers in patients with collagen vascular diseases. Int J Immunother 1987; 3: 271 â 7.
dc.identifier.citedreferenceMartin MF, Dowd PM, Ring EF, Cooke ED, Dieppe PA, Kirby JD. Prostaglandin E1 infusions for vascular insufficiency in progressive systemic sclerosis. Ann Rheum Dis 1981; 40: 350 â 4.
dc.identifier.citedreferenceDowd PM, Martin MF, Cooke ED, Bowcock SA, Jones R, Dieppe PA, et al. Treatment of Raynaud’s phenomenon by intravenous infusion of prostacyclin (PGI2). Br J Dermatol 1982; 106: 81 â 9.
dc.identifier.citedreferenceClifford PC, Martin MF, Sheddon EJ, Kirby JD, Baird RN, Dieppe PA. Treatment of vasospastic disease with prostaglandin E1. Br Med J 1980; 281: 1031 â 4.
dc.identifier.citedreferenceMcHugh NJ, Csuka M, Watson H, Belcher G, Amadi A, Ring EF, et al. Infusion of iloprost, a prostacyclin analogue, for treatment of Raynaud’s phenomenon in systemic sclerosis. Ann Rheum Dis 1988; 47: 43 â 7.
dc.identifier.citedreferenceKyle V, Parr G, Salisbury R, Thomas PP, Hazleman B. Prostaglandin E1 vasospastic disease and thermography. Ann Rheum Dis 1985; 44: 73 â 8.
dc.identifier.citedreferenceKyle MV, Belcher G, Hazleman BL. Placebo controlled study showing therapeutic benefit of iloprost in the treatment of Raynaud’s phenomenon. J Rheumatol 1992; 19: 1403 â 6.
dc.identifier.citedreferenceKlimiuk PS, Kay EA, Mitchell WS, Taylor L, Gush R, Gould S, et al. Ketanserin: an effective treatment regimen for digital ischaemia in systemic sclerosis. Scand J Rheumatol 1989; 18: 107 â 11.
dc.identifier.citedreferenceSteen VD, Medsger TA Jr. The value of the Health Assessment Questionnaire and special patientâ generated scales to demonstrate change in systemic sclerosis patients over time. Arthritis Rheum 1997; 40: 1984 â 91.
dc.identifier.citedreferenceSelenkoâ Gebauer N, Duschek N, Minimair G, Stingl G, Karlhofer F. Successful treatment of patients with severe secondary Raynaud’s phenomenon with the endothelin receptor antagonist bosentan. Rheumatology (Oxford) 2006; 45 Suppl 3: iii45 â 8.
dc.identifier.citedreferenceHerrick AL, Hollis S, Schofield D, Rieley F, Blann A, Griffin K, et al. A doubleâ blind placeboâ controlled trial of antioxidant therapy in limited cutaneous systemic sclerosis. Clin Exp Rheumatol 2000; 18: 349 â 56.
dc.identifier.citedreferenceBraun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychol 2006; 3: 77 â 101.
dc.identifier.citedreferenceColeiro B, Marshall SE, Denton CP, Howell K, Blann A, Welsh KI, et al. Treatment of Raynaud’s phenomenon with the selective serotonin reuptake inhibitor fluoxetine. Rheumatology (Oxford) 2001; 40: 1038 â 43.
dc.identifier.citedreferenceBlack CM, Halkierâ Sorensen L, Belch JJ, Ullman S, Madhok R, Smit AJ, et al. Oral iloprost in Raynaud’s phenomenon secondary to systemic sclerosis: a multicentre, placeboâ controlled, doseâ comparison study. Br J Rheumatol 1998; 37: 952 â 60.
dc.identifier.citedreferenceWigley FM, Korn JH, Csuka ME, Medsger TA Jr, Rothfield NF, Ellman M, et al. Oral iloprost treatment in patients with Raynaud’s phenomenon secondary to systemic sclerosis: a multicenter, placeboâ controlled, doubleâ blind study. Arthritis Rheum 1998; 41: 670 â 7.
dc.identifier.citedreferenceMerkel PA, Herlyn K, Martin RW, Anderson JJ, Mayes MD, Bell P, et al. Measuring disease activity and functional status in patients with scleroderma and Raynaud’s phenomenon. Arthritis Rheum 2002; 46: 2410 â 20.
dc.identifier.citedreferenceMerkel PA, Clements PJ, Reveille JD, Suarezâ Almazor ME, Valentini G, Furst DE. Current status of outcome measure development for clinical trials in systemic sclerosis: report from OMERACT 6. J Rheumatol 2003; 30: 1630 â 47.
dc.identifier.citedreferenceKhanna D, Lovell DJ, Giannini E, Clements PJ, Merkel PA, Seibold JR, et al. Development of a provisional core set of response measures for clinical trials of systemic sclerosis. Ann Rheum Dis 2008; 67: 703 â 9.
dc.identifier.citedreferencePauling JD, Shipley JA, Hart DJ, McGrogan A, McHugh NJ. Use of laser speckle contrast imaging to assess digital microvascular function in primary Raynaud phenomenon and systemic sclerosis: a comparison using the Raynaud condition score diary. J Rheumatol 2015; 42: 1163 â 8.
dc.identifier.citedreferencePauling JD, Frech TV, Hughes M, Gordon JK, Domsic T, Anderson ME, et al. Patientâ reported outcome instruments for assessing Raynaudâ s phenomenon in systemic sclerosis: a SCTC vascular working group report. J Scleroderm Relat Dis 2018. https://doi.org/10.1177/2397198318774307.
dc.identifier.citedreferencePauling JD, Frech TM, Domsic RT, Hudson M. Patient participation in patientâ reported outcome instrument development in systemic sclerosis. Clin Exp Rheumatol. 2017; 35 Suppl 106: 184 â 92.
dc.identifier.citedreferenceKirwan JR, Tugwell PS. Overview of the patient perspective at OMERACT 10: conceptualizing methods for developing patientâ reported outcomes. J Rheumatol 2011; 38: 1699 â 701.
dc.identifier.citedreferenceBotzoris V, Drosos AA. Management of Raynaud’s phenomenon and digital ulcers in systemic sclerosis. Joint Bone Spine 2011; 78: 341 â 6.
dc.identifier.citedreferenceVoulgari PV, Alamanos Y, Papazisi D, Christou K, Papanikolaou C, Drosos AA. Prevalence of Raynaud’s phenomenon in a healthy Greek population. Ann Rheum Dis 2000; 59: 206 â 10.
dc.identifier.citedreferenceWalker UA, Tyndall A, Czirjak L, Denton C, Fargeâ Bancel D, Kowalâ Bielecka O, et al. Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group database. Ann Rheum Dis 2007; 66: 754 â 63.
dc.identifier.citedreferenceBassel M, Hudson M, Taillefer SS, Schieir O, Baron M, Thombs BD. Frequency and impact of symptoms experienced by patients with systemic sclerosis: results from a Canadian National Survey. Rheumatology (Oxford) 2011; 50: 762 â 7.
dc.identifier.citedreferenceWillems LM, Kwakkenbos L, Leite CC, Thombs BD, van den Hoogen FH, Maia AC, et al. Frequency and impact of disease symptoms experienced by patients with systemic sclerosis from five European countries. Clin Exp Rheumatol 2014; 32 Suppl 86: S88 â 93.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
acr23475.pdf
Size:
232.1KB
Format:
PDF
View/Open
Name:
acr23475_am.pdf
Size:
348.9KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.